MoonLake Immunotherapeutics

Forecast & Rating15 analysts currently cover MoonLake Immunotherapeutics, with about 73.3% giving a positive rating — meaning they expect the stock to rise. The average price target is $28.54, about 131.1% upside from the current price of $12.35. Price targets range from $6.00 to $50.00 — a wide spread, showing clear disagreement over just how much MoonLake Immunotherapeutics can rise. Historically, about 44.6% of past price targets were eventually met, which adds credibility. For you, this means most professionals who study MoonLake Immunotherapeutics closely still see room for the stock to rise. Data as of Sep 13, 2026; for reference only and not investment advice.